{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T15:02:40Z","timestamp":1781881360102,"version":"3.54.5"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008425","name":"Government of Galicia Department of Education Science Universities and Professional Training","doi-asserted-by":"publisher","award":["ED431B 2023\/25"],"award-info":[{"award-number":["ED431B 2023\/25"]}],"id":[{"id":"10.13039\/501100008425","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Foundation for Science and Technology","doi-asserted-by":"publisher","award":["LA\/P\/0140\/2020"],"award-info":[{"award-number":["LA\/P\/0140\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Foundation for Science and Technology","doi-asserted-by":"publisher","award":["UID\/50006\/2025"],"award-info":[{"award-number":["UID\/50006\/2025"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Foundation for Science and Technology","doi-asserted-by":"publisher","award":["UIDB\/04378\/2020"],"award-info":[{"award-number":["UIDB\/04378\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Foundation for Science and Technology","doi-asserted-by":"publisher","award":["SFRH\/BD\/147463\/2019"],"award-info":[{"award-number":["SFRH\/BD\/147463\/2019"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Foundation for Science and Technology","doi-asserted-by":"publisher","award":["UI\/BD\/154888\/2023"],"award-info":[{"award-number":["UI\/BD\/154888\/2023"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018886","name":"Laborat\u00f3rio Associado para a Qu\u00edmica Verde","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018886","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"State Agency of Research","doi-asserted-by":"publisher","award":["PID2021-124010OB-100"],"award-info":[{"award-number":["PID2021-124010OB-100"]}],"id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.biopha.2026.119091","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T11:15:59Z","timestamp":1770894959000},"page":"119091","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Discovery of first-in-class melanostatin-based ago-allosteric modulators of the dopamine D2 receptors"],"prefix":"10.1016","volume":"196","author":[{"given":"Hugo F.","family":"Costa-Almeida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1440-9873","authenticated-orcid":false,"given":"Xavier C.","family":"Correia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara C.","family":"Silva-Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1464-7254","authenticated-orcid":false,"given":"Beatriz L.","family":"Pires-Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera M.","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5218-6351","authenticated-orcid":false,"given":"Xerardo","family":"Garc\u00eda-Mera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eddy","family":"Sotelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Brea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda I.","family":"Loza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e9lix","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 E.","family":"Rodr\u00edguez-Borges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9071-6197","authenticated-orcid":false,"given":"Ivo E.","family":"Sampaio-Dias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.biopha.2026.119091_bib1","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/S0006-291X(71)80026-8","article-title":"Isolation and structure of hypothalamic MSH release-inhibition hormone","volume":"43","author":"Nair","year":"1971","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"8","key":"10.1016\/j.biopha.2026.119091_bib2","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1055\/a-1695-1095","article-title":"A convenient on-site oxidation strategy for the N-hydroxylation of melanostatin neuropeptide using Cope elimination","volume":"54","author":"Sampaio-Dias","year":"2022","journal-title":"Synthesis"},{"issue":"6","key":"10.1016\/j.biopha.2026.119091_bib3","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/0196-9781(82)90055-9","article-title":"Inhibition by L-prolyl-L-leucyl-glycinamide (PLG) of alpha-melanocyte stimulating hormone release from hypothalamic slices","volume":"3","author":"Scimonelli","year":"1982","journal-title":"Peptides"},{"issue":"4","key":"10.1016\/j.biopha.2026.119091_bib4","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0196-9781(80)90006-6","article-title":"Opiate receptor antagonism by L-prolyl-L-leucyl-glycinamide, MIF-I","volume":"1","author":"Dickinson","year":"1980","journal-title":"Peptides"},{"issue":"2","key":"10.1016\/j.biopha.2026.119091_bib5","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0014-2999(79)90156-0","article-title":"Antagonism of morphine-induced catalepsy by L-prolyl-L-leucyl-glycinamide","volume":"53","author":"Chiu","year":"1979","journal-title":"Eur. J. Pharm."},{"issue":"23","key":"10.1016\/j.biopha.2026.119091_bib6","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/0024-3205(86)90391-7","article-title":"Existence of antiopiate systems as illustrated by MIF-1\/Tyr-MIF-1","volume":"39","author":"Galina","year":"1986","journal-title":"Life Sci."},{"issue":"1-2","key":"10.1016\/j.biopha.2026.119091_bib7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3109\/00207459008994244","article-title":"MIF-induced augmentation of melatonin functions: possible relevance to mechanisms of action of MIF-1 in movement disorders","volume":"52","author":"Sandyk","year":"1990","journal-title":"Int. J. Neurosci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119091_bib8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd2760","article-title":"Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders","volume":"8","author":"Conn","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.biopha.2026.119091_bib9","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/j.1471-4159.1988.tb03005.x","article-title":"Interaction of L-prolyl-L-leucyl glycinamide with dopamine D2 receptor: evidence for modulation of agonist affinity states in bovine striatal membranes","volume":"50","author":"Srivastava","year":"1988","journal-title":"J. Neurochem."},{"issue":"1","key":"10.1016\/j.biopha.2026.119091_bib10","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0304-3940(99)00413-9","article-title":"Modulation of agonist stimulated adenylyl cyclase and GTPase activity by L-pro-L-leu-glycinamide and its peptidomimetic analogue in rat striatal membranes","volume":"269","author":"Mishra","year":"1999","journal-title":"Neurosci. Lett."},{"issue":"3","key":"10.1016\/j.biopha.2026.119091_bib11","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1124\/jpet.105.091256","article-title":"Modulation of agonist binding to human dopamine receptor subtypes by L-prolyl-L-leucyl-glycinamide and a peptidomimetic analog","volume":"315","author":"Verma","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2026.119091_bib12","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0196-9781(81)80019-8","article-title":"Effect of L-prolyl-L-leucyl-glycinamide (PLG) on neuroleptic-induced catalepsy and dopamine\/neuroleptic receptor bindings","volume":"2","author":"Chiu","year":"1981","journal-title":"Peptides"},{"key":"10.1016\/j.biopha.2026.119091_bib13","article-title":"Dopamine receptors: is it possible to become a therapeutic target for depression?","volume":"13","author":"Zhao","year":"2022","journal-title":"Front. Pharm."},{"issue":"6","key":"10.1016\/j.biopha.2026.119091_bib14","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/sj.mp.4001507","article-title":"Dopamine in drug abuse and addiction: results from imaging studies and treatment implications","volume":"9","author":"Volkow","year":"2004","journal-title":"Mol. Psychiatry"},{"issue":"1","key":"10.1016\/j.biopha.2026.119091_bib15","doi-asserted-by":"crossref","first-page":"4959","DOI":"10.1038\/s41598-023-31250-2","article-title":"Striatal dopamine D2-like receptors availability in obesity and its modulation by bariatric surgery: a systematic review and meta-analysis","volume":"13","author":"Ribeiro","year":"2023","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2026.119091_bib16","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/2047-9158-1-6","article-title":"Linking restless legs syndrome with Parkinson's disease: clinical, imaging and genetic evidence","volume":"1","author":"Peeraully","year":"2012","journal-title":"Transl. Neurodegener."},{"issue":"4","key":"10.1016\/j.biopha.2026.119091_bib17","first-page":"303","article-title":"Melanocyte-stimulating-hormone release-inhibiting factor-I and tardive dyskinesia","volume":"38","author":"Ehrensing","year":"1977","journal-title":"Dis. Nerv. Syst"},{"key":"10.1016\/j.biopha.2026.119091_bib18","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ejmech.2013.08.001","article-title":"Synthesis and allosteric modulation of the dopamine receptor by peptide analogs of L-prolyl-L-leucyl-glycinamide (PLG) modified in the L-proline or L-proline and L-leucine scaffolds","volume":"69","author":"da Costa","year":"2013","journal-title":"Eur. J. Med. Chem."},{"issue":"47","key":"10.1016\/j.biopha.2026.119091_bib19","doi-asserted-by":"crossref","first-page":"11065","DOI":"10.1039\/C6OB02248K","article-title":"Novel L-prolyl-L-leucylglycinamide (PLG) tripeptidomimetics based on a 2-azanorbornane scaffold as positive allosteric modulators of the D2R","volume":"14","author":"Sampaio-Dias","year":"2016","journal-title":"Org. Biomol. Chem."},{"issue":"8","key":"10.1016\/j.biopha.2026.119091_bib20","doi-asserted-by":"crossref","first-page":"3690","DOI":"10.1021\/acschemneuro.9b00259","article-title":"Synthesis, pharmacological, and biological evaluation of MIF-1 picolinoyl peptidomimetics as positive allosteric modulators of D2R","volume":"10","author":"Sampaio-Dias","year":"2019","journal-title":"ACS Chem. Neurosci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119091_bib21","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1021\/acschemneuro.0c00687","article-title":"Synthesis, pharmacological, and biological evaluation of 2-furoyl-based MIF-1 peptidomimetics and the development of a general-purpose model for allosteric modulators (ALLOPTML)","volume":"12","author":"Sampaio-Dias","year":"2021","journal-title":"ACS Chem. Neurosci."},{"issue":"9","key":"10.1016\/j.biopha.2026.119091_bib22","doi-asserted-by":"crossref","first-page":"6209","DOI":"10.1021\/acs.jmedchem.1c00252","article-title":"Discovery of new potent positive allosteric modulators of dopamine D2 receptors: insights into the bioisosteric replacement of proline to 3-furoic acid in the melanostatin neuropeptide","volume":"64","author":"Sampaio-Dias","year":"2021","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.biopha.2026.119091_bib23","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1021\/acsmedchemlett.3c00264","article-title":"Stapling amantadine to melanostatin neuropeptide: discovery of potent positive allosteric modulators of the D2 receptors","volume":"14","author":"Silva-Reis","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"issue":"3","key":"10.1016\/j.biopha.2026.119091_bib24","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0306-3623(82)90090-8","article-title":"The effects of prolyl-leucyl-glycine amide on drug-induced rotation in lesioned rats","volume":"13","author":"Smith","year":"1982","journal-title":"Gen. Pharm."},{"issue":"2","key":"10.1016\/j.biopha.2026.119091_bib25","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0196-9781(97)00321-5","article-title":"Protection against MPTP treatment by an analog of Pro-Leu-Gly-NH2 (PLG, MIF-1)","volume":"19","author":"Marcotte","year":"1998","journal-title":"Peptides"},{"issue":"2","key":"10.1016\/j.biopha.2026.119091_bib26","first-page":"120","article-title":"Double-blind evaluation of oral L-prolyl-L-leucyl-glycine amide in Parkinson's disease","volume":"114","author":"Barbeau","year":"1976","journal-title":"Can. Med. Assoc. J."},{"issue":"11","key":"10.1016\/j.biopha.2026.119091_bib27","first-page":"1079","article-title":"Preliminary clinical studies with L-prolyl-L-leucyl-glycine amide in Parkinson's disease","volume":"107","author":"Kastin","year":"1972","journal-title":"Can. Med. Assoc. J."},{"issue":"5-6","key":"10.1016\/j.biopha.2026.119091_bib28","first-page":"360","article-title":"Effect of melanocyte-stimulating hormone-release inhibiting factor (MIF) in Parkinson\u2019s syndrom","volume":"12","author":"Fischer","year":"1974","journal-title":"Eur. Neurol."},{"issue":"7937","key":"10.1016\/j.biopha.2026.119091_bib29","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0140-6736(75)90778-3","article-title":"Potentiation of levodopa effect by intravenous L-prolyl-L-leucyl-glycine amide in man","volume":"306","author":"Barbeau","year":"1975","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2026.119091_bib30","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1002\/ana.10513","article-title":"Limitations of current Parkinson's disease therapy","volume":"53","author":"Rascol","year":"2003","journal-title":"Ann. Neurol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119091_bib31","doi-asserted-by":"crossref","first-page":"770","DOI":"10.3390\/pharmaceutics15030770","article-title":"Current treatments and new, tentative therapies for Parkinson\u2019s disease","volume":"15","author":"Pardo-Moreno","year":"2023","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.biopha.2026.119091_bib32","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2174\/1570159X14666151120123025","article-title":"Current pharmaceutical treatments and alternative therapies of Parkinson's disease","volume":"14","author":"Dong","year":"2016","journal-title":"Curr. Neuropharmacol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119091_bib33","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00003495-197611050-00001","article-title":"Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism","volume":"11","author":"Pinder","year":"1976","journal-title":"Drugs"},{"key":"10.1016\/j.biopha.2026.119091_bib34","first-page":"S32","article-title":"Problems with long-term levodopa therapy for Parkinson's disease","volume":"17","author":"Marsden","year":"1994","journal-title":"Clin. Neuropharmacol"},{"issue":"22","key":"10.1016\/j.biopha.2026.119091_bib35","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/0024-3205(71)90326-2","article-title":"DOPA potentiation by a hypothalamic factor, MSH release-inhibiting hormone (MIF)","volume":"10","author":"Plotnikoff","year":"1971","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119091_bib36","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0196-9781(94)90165-1","article-title":"Opposite direction of transport across the blood-brain barrier for Tyr-MIF-1 and MIF-1: comparison with morphine","volume":"15","author":"Banks","year":"1994","journal-title":"Peptides"},{"issue":"1","key":"10.1016\/j.biopha.2026.119091_bib37","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3181\/00379727-148-38484","article-title":"Significant differences in the degradation of Pro-Leu-Gly-NH2 by human serum and that of other species (38484)","volume":"148","author":"Walter","year":"1975","journal-title":"Proc. Soc. Exp. Biol. Med."},{"issue":"8","key":"10.1016\/j.biopha.2026.119091_bib38","doi-asserted-by":"crossref","first-page":"6191","DOI":"10.1021\/acs.jmedchem.2c00094","article-title":"On the utility of chemical strategies to improve peptide gut stability","volume":"65","author":"Kremsmayr","year":"2022","journal-title":"J. Med. Chem."},{"issue":"23","key":"10.1016\/j.biopha.2026.119091_bib39","doi-asserted-by":"crossref","first-page":"9718","DOI":"10.1021\/jm5010896","article-title":"Peptides containing \u03b2-amino acid patterns: challenges and successes in medicinal chemistry","volume":"57","author":"Cabrele","year":"2014","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.biopha.2026.119091_bib40","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00726-005-0212-y","article-title":"Alicyclic beta-amino acids in medicinal chemistry","volume":"29","author":"Kuhl","year":"2005","journal-title":"Amino Acids"},{"issue":"4","key":"10.1016\/j.biopha.2026.119091_bib41","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1039\/b501173f","article-title":"Application of alicyclic \u03b2-amino acids in peptide chemistry","volume":"35","author":"F\u00fcl\u00f6p","year":"2006","journal-title":"Chem. Soc. Rev."},{"issue":"1","key":"10.1016\/j.biopha.2026.119091_bib42","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1399-3011.1990.tb00718.x","article-title":"Morphiceptin analogs containing 2-aminocyclopentane carboxylic acid as a peptidomimetic for proline","volume":"35","author":"Mierke","year":"1990","journal-title":"Int. J. Pept. Protein Res."},{"issue":"1","key":"10.1016\/j.biopha.2026.119091_bib43","doi-asserted-by":"crossref","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"issue":"1-3","key":"10.1016\/j.biopha.2026.119091_bib44","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"18","key":"10.1016\/j.biopha.2026.119091_bib45","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1016\/j.tetasy.2004.05.029","article-title":"Advanced procedure for the enzymatic ring opening of unsaturated alicyclic \u03b2-lactams","volume":"15","author":"Forr\u00f3","year":"2004","journal-title":"Tetrahedron Asymmetry"},{"key":"10.1016\/j.biopha.2026.119091_bib46","first-page":"2445","article-title":"Novel 1,2-disubstituted carbocyclic nucleoside analogues of purine with a cyclopentene ring","volume":"16","author":"Besada","year":"2002","journal-title":"Synthesis"},{"issue":"13","key":"10.1016\/j.biopha.2026.119091_bib47","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1021\/jm991013u","article-title":"Structure-based design, synthesis, and X-ray crystallography of a high-affinity antagonist of the Grb2-SH2 domain containing an asparagine mimetic","volume":"42","author":"Furet","year":"1999","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.biopha.2026.119091_bib48","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1021\/acschemneuro.8b00083","article-title":"Perturbation theory\/machine learning model of ChEMBL data for dopamine targets: docking, synthesis, and assay of new L-prolyl-L-leucyl-glycinamide peptidomimetics","volume":"9","author":"da Costa","year":"2018","journal-title":"ACS Chem. Neurosci."},{"issue":"10","key":"10.1016\/j.biopha.2026.119091_bib49","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1021\/jm00160a052","article-title":"Synthesis of Pro-Leu-Gly-NH2 analogues modified at the prolyl residue and evaluation of their effects on the receptor binding activity of the central dopamine receptor agonist, ADTN","volume":"29","author":"Johnson","year":"1986","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.biopha.2026.119091_bib50","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1021\/jm050644n","article-title":"Design and synthesis of photoaffinity-labeling ligands of the L-prolyl-L-leucylglycinamide binding site involved in the allosteric modulation of the dopamine receptor","volume":"49","author":"Fisher","year":"2006","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.biopha.2026.119091_bib51","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13024-017-0149-0","article-title":"The SH-SY5Y cell line in Parkinson\u2019s disease research: a systematic review","volume":"12","author":"Xicoy","year":"2017","journal-title":"Mol. Neurodegener."},{"issue":"2-3","key":"10.1016\/j.biopha.2026.119091_bib52","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.toxlet.2012.11.015","article-title":"Neurotoxicity of \"ecstasy\" and its metabolites in human dopaminergic differentiated SH-SY5Y cells","volume":"216","author":"Ferreira","year":"2013","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.biopha.2026.119091_bib53","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s00204-013-1120-7","article-title":"The mixture of \"ecstasy\" and its metabolites is toxic to human SH-SY5Y differentiated cells at in vivo relevant concentrations","volume":"88","author":"Barbosa","year":"2014","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.biopha.2026.119091_bib54","article-title":"Differentiation of the SH-SY5Y human neuroblastoma cell line","volume":"108","author":"Shipley","year":"2016","journal-title":"J. Vis. Exp."},{"issue":"5","key":"10.1016\/j.biopha.2026.119091_bib55","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.freeradbiomed.2006.12.004","article-title":"Molecular mechanisms of 6-hydroxydopamine-induced cytotoxicity in PC12 cells: involvement of hydrogen peroxide-dependent and -independent action","volume":"42","author":"Saito","year":"2007","journal-title":"Free Radic. Biol. Med."},{"issue":"8","key":"10.1016\/j.biopha.2026.119091_bib56","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1021\/acsmedchemlett.5c00287","article-title":"Proline homologation in melanostatin neuropeptide: discovery of potent modulators of the dopamine D2 receptors","volume":"16","author":"Sampaio-Dias","year":"2025","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.biopha.2026.119091_bib57","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jorganchem.2018.01.003","article-title":"Performance of chiral tetracarbonylmolybdenum pyrindanyl amine complexes in catalytic olefin epoxidation","volume":"858","author":"Neves","year":"2018","journal-title":"J. Organomet. Chem."},{"issue":"12","key":"10.1016\/j.biopha.2026.119091_bib58","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1039\/C6QO00330C","article-title":"On the scope of oxidation of tertiary amines: Meisenheimer rearrangements versus Cope elimination in 2-(cyanoethyl)-2-azanorbornanes","volume":"3","author":"Sousa","year":"2016","journal-title":"Org. Chem. Front."},{"issue":"126","key":"10.1016\/j.biopha.2026.119091_bib59","doi-asserted-by":"crossref","first-page":"104509","DOI":"10.1039\/C5RA24868J","article-title":"Enantiopure synthesis of 7-(1-pyrindanyl)propargyl ethers as rasagiline analogues via chemical or enzymatic resolution of 1-pyrindan-7-ol","volume":"5","author":"Sousa","year":"2015","journal-title":"RSC Adv."},{"issue":"21","key":"10.1016\/j.biopha.2026.119091_bib60","doi-asserted-by":"crossref","first-page":"7512","DOI":"10.1021\/jo971176v","article-title":"NMR chemical shifts of common laboratory solvents as trace impurities","volume":"62","author":"Gottlieb","year":"1997","journal-title":"J. Org. Chem."},{"issue":"23","key":"10.1016\/j.biopha.2026.119091_bib61","doi-asserted-by":"crossref","first-page":"8786","DOI":"10.1021\/jo701332v","article-title":"Diastereo- and enantioselective synthesis of orthogonally protected 2,4-diaminocyclopentanecarboxylates: a flip from \u03b2-amino- to \u03b2,\u03b3-diaminocarboxylates","volume":"72","author":"Kiss","year":"2007","journal-title":"J. Org. Chem."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222600123X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222600123X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T14:48:56Z","timestamp":1781880536000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075333222600123X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":61,"alternative-id":["S075333222600123X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119091","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of first-in-class melanostatin-based ago-allosteric modulators of the dopamine D2 receptors","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119091","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119091"}}